Skip to main content
. Author manuscript; available in PMC: 2017 Jul 14.
Published in final edited form as: Breast Cancer Res Treat. 2016 May 13;157(2):253–265. doi: 10.1007/s10549-016-3829-5

Figure 6. ESR1 mutation do not predict outcomes in patient treated with adjuvant Tam.

Figure 6

a, ddPCR analysis showing allele frequencies of three HBD-ESR1 mutations in primary breast cancers. b and c, Kaplan–Meier analysis of RFS (b), and OS (c). (d) Heatmaps of mRNA levels of genes involved in IGF-1 signaling pathway comparing MCF-7 and ZR-75B stable. Immunoblot analysis to detect phosphorylation and total protein expression of IGF1Rβ, pIRS-1, p85 and p55; GAPDH was used as a loading control (e). Immunoblot of cells transduced with siRNAs for p55 and p85. (f). Cells were also plated in soft agar assays and treated with vehicle (-) or with Tam (10 and 100nM). Experiments were performed in triplicate and error bars indicate SD. ns, not significant. *P<0.05; ***P<0.001.